Short summary

Although there are effective drugs such as bisphosphonates that reduce the risk of fracture in patients with osteoporosis, these drugs are untested in patients with kidney disease where the biology of the bone disease leading to bone fragility can be different. In addition some data suggests that these first-line bone therapies may worsen kidney function. Patients with kidney disease were under-represented or excluded from most randomised clinical trials as were patients with other significant biochemical abnormal findings, leaving a gap in the current medical knowledge about the potential benefits and risks of these medications in this growing group of the population. This evidence gap has led some to use untested treatment regimens in an attempt to reduce the risk of fracture.

Rationale

This observational study will examine the incidence rate of adverse effects, worsening of renal function, and effects on fracture rates and Bone Mineral Density using routinely collected treatment data from a real world population.

Description of the cohort

Patients examined for osteoporosis with BMD measurements under the auspices of the Department of Endocrinology, Odense University Hospital.

Data and biological material

Results of DXA scans.
Clinical Biochemistry.
Linkage through Statistics Denmark for adverse events, fractures and causes of death.

Collaborating researchers and departments

OPEN Odense Patient data Explorative Network, Odense University Hospital

• Professor and Consultant Endocrinologist Bo Abrahamsen, PhD

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

• Associate Professor Daniel Prieto-Alhambra

Department of Endocrinology, Odense University Hospital

• Consultant Wndocrinologist Pernille Hermann, PhD
• Consultant Clinical Biochemist Mads Nybo, PhD